跳至主要内容
临床试验/PACTR202201655513401
PACTR202201655513401尚未招募未知

Efficacy and safety of four-weeks versus twelve-weeks loading doses spacing of intravitreal Aflibercept for treatment of macular edema associated with Central Retinal Vein Occlusion

Egypt health insurance0 个研究点目标入组 60 人开始时间: 2022年1月6日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
All

入选标准

  • Any participant to be included in the study should have:
  • normal or controlled blood pressure.
  • normal Hba1c or controlled (maximum 6.5%).
  • normal or controlled lipogram.
  • Patients aged =18 years with center-involved macular edema due to CRVO (CMT =250 µm on OCT).
  • Best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 to 24 letters)

排除标准

  • Exclusion criteria comprised the following:
  • pregnancy or lactation.
  • previous vitreoretinal or filtration surgery.
  • iris neovascularization.
  • any systemic or ocular disorder in the study eye that may confound the interpretation of the study results.
  • previous treatment with any anti-VEGF agents.
  • systemic anti-angiogenic medications.
  • intraocular corticosteroids

研究者

发起方
Egypt health insurance

相似试验